Buse, John B.

Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure

Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 118

Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study

Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Perkins, B. A., Welsh, J. B., Willi, S. M., et al. (2011) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 118

Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial

Bethel, M. A., Mentz, R. J., Merrill, P., Buse, J. B., Chan, J. C., Goodman, S. G., Iqbal, N., Jakuboniene, N., Katona, B., Lokhnygina, Y., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 112

Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: A STICH protocol

Garg, S. K., Peters, A. L., Buse, J. B., & Danne, T. (2018) · Diabetes Technology & Therapeutics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 108

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

Verma, S., Bhatt, D. L., Bain, S. C., Buse, J. B., Mann, J. F. E., Marso, S. P., Nauck, M. A., Poulter, N. R., Pratley, R. E., Zinman, B., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 105

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 94

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial

Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care

Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Cited by 94

Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus.

Kusari, J., Verma, U. S., Buse, J. B., Henry, R. R., & Olefsky, J. M. (1991) · Journal of Clinical Investigation

Metabolism, Diabetes, and CancerGenetic Associations and Epidemiology

Cited by 90

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care

Diabetes Treatment and ManagementPancreatitis Pathology and Treatment

Cited by 87

Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the tecos trial

Sharma, A., Green, J. B., Dunning, A., Lokhnygina, Y., Al-Khatib, S. M., Lopes, R. D., Buse, J. B., Lachin, J. M., Van de Werf, F., Armstrong, P. W., et al. (2017) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 80

Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype

Standl, E., Stevens, S. R., Armstrong, P. W., Buse, J. B., Chan, J. C. N., Green, J. B., Lachin, J. M., Scheen, A., Travert, F., Van de Werf, F., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 76

Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial

Marx, N., Deanfield, J. E., Mann, J. F. E., Arechavaleta, R., Bain, S. C., Bajaj, H. S., Bayer Tanggaard, K., Birkenfeld, A. L., Buse, J. B., Davicevic-Elez, Z., et al. (2025) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 70

Molecular Scanning of Insulin-Responsive Glucose Transporter (GLUT4) Gene in NIDDM Subjects

Choi, W.-H., O'Rahilly, S., Buse, J. B., Rees, A., Morgan, R., Flier, J. S., & Moller, D. E. (1991) · Diabetes

Metabolism, Diabetes, and CancerGenetic Associations and Epidemiology

Cited by 70

Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial.

Nauck, M. A., Muus Ghorbani, M. L., Kreiner, E., Saevereid, H. A., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2019) · Diabetes Care

Diabetes Treatment and ManagementGallbladder and Bile Duct Disorders

Cited by 69

Confirming the bidirectional nature of the association between severe hypoglycemic and cardiovascular events in type 2 diabetes: insights from EXSCEL

Standl, E., Stevens, S. R., Lokhnygina, Y., Bethel, M. A., Buse, J. B., Gustavson, S. M., Maggioni, A. P., Mentz, R. J., Hernandez, A. F., & Holman, R. R. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 65

Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials

Lee, M. M. Y., Sattar, N., Pop-Busui, R., Deanfield, J., Emerson, S. S., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N. R., et al. (2025) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 63

Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes

Barlowe, T. S., Anderson, C., Sandler, R. S., Subramaniam, D., Muratore, A., Buse, J. B., Gouker, L. N., Majithia, R. T., Shaheen, N. J., Stürmer, T., et al. (2025) · Clinical Gastroenterology and Hepatology

Diabetes Treatment and ManagementGastrointestinal Bleeding Diagnosis and Treatment

Cited by 55

Long-term effects of intensive glycemic and blood pressure control and fenofibrate use on kidney outcomes

Mottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 48

Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial

Crowley, M. J., McGuire, D. K., Alexopoulos, A.-S., Jensen, T. J., Rasmussen, S., Saevereid, H. A., Verma, S., & Buse, J. B. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 47

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

Leiter, L. A., Bain, S. C., Bhatt, D. L., Buse, J. B., Mazer, C. D., Pratley, R. E., Rasmussen, S., Ripa, M. S., Vrazic, H., & Verma, S. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 45

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

Bethel, M. A., Patel, R. A., Thompson, V. P., Merrill, P., Reed, S. D., Li, Y., Ahmadi, S., Katona, B. G., Gustavson, S. M., Ohman, P., et al. (2019) · Diabetes Care

Thyroid Cancer Diagnosis and TreatmentThyroid Disorders and Treatments

Cited by 43

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial

Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 39

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: A 52-week, randomized, open-label extension of the PIONEER 7 trial

Buse, J. B., Bode, B. W., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Nielsen, M. A., & Pieber, T. R. (2020) · BMJ Open Diabetes Research & Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 38

Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence

Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 37